BioSpace News Archive

Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, will be presenting new preclinical in vivo data on improving oligo delivery to the liver in an online poster presentation at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society, held virtually from September 26th to 29th, 2021.

Syndax Pharmaceuticals, Inc. and Incyte announced that they have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax’s anti-CSF-1R monoclonal antibody.

Greenwich LifeSciences, Inc. announced that CEO Snehal Patel will present at the Benzinga Healthcare Small-Cap Conference being held September 29-30, 2021.

Cardinal Health plans to release first-quarter financial results for its fiscal year 2022 on November 9 prior to the opening of trading on the New York Stock Exchange.

Microbix Biosystems Inc., a life sciences innovator and exporter, announces that it has been invited to present about the performance of its COVID-19 test quality assessment products at “AACC” the annual scientific meeting & clinical laboratory exposition of the American Association of Clinical Chemistry, taking place in live and virtual formats from Atlanta, GA, September 26-30, 2021.

Ocuphire Pharma, Inc. announced that Mina Sooch, President and Chief Executive Officer will be presenting corporate overviews at the Benzinga Healthcare Small Cap Conference on Wednesday, September 29th.

Omega Therapeutics, Inc. today announced that Mahesh Karande , President and Chief Executive Officer, will participate in a fireside chat at the Chardan Virtual 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 8:30 a.m. ET.

Tvardi Therapeutics (“Tvardi”) today announced that Fierce Biotech has named it as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Ensysce Biosciences, Inc. announced today that it has entered into a securities purchase agreement with institutional investors (“Investors”) in the form of senior secured convertible notes

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat during Roivant R&D Day 2021 on Tuesday, September 28, 2021 at 4:00 p.m. ET.